Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230333 | 0.86 | TP53 (0.44) | TP53MAPTPOLBBLM | |
| SCHEMBL30526270 | 0.73 | TP53 (0.56) | TP53MAPTPOLBBLM | |
| SCHEMBL10837757 | 0.73 | TP53 (0.56) | TP53MAPTPOLBBLM | |
| SCHEMBL20280946 | 0.73 | TP53 (0.56) | TP53MAPTPOLBBLM | |
| SCHEMBL20281057 | 0.73 | POLB (0.57) | MAPTPOLB | |
| SCHEMBL20280937 | 0.73 | HIF1A (0.46) | TP53MAPT | |
| SCHEMBL20280939 | 0.72 | HDAC3 (0.42) | TP53MAPT | |
| SCHEMBL8758459 | 0.72 | NPY1R (0.56) | NPY1RNPY5RTP53MAPTPOLB | |
| SCHEMBL23260498 | 0.69 | EHMT2 (0.62) | TP53MAPTPOLBBLM | |
| SCHEMBL10837396 | 0.69 | KDM4E (0.48) | TP53MAPTPOLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814372-B2 | Agonists of EPHA and their uses | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20190002446-A1 | AGONISTS OF EPHA AND THEIR USES | CASE WESTERN RESERVE UNIVERSITY | 2019-01-03 | — | — | US | disclosed |
| US-8377948-B2 | Antitumor agents and methods of their use | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377948-B2 | Antitumor agents and methods of their use | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377948-B2 | Antitumor agents and methods of their use | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090048265-A1 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048265-A1 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048265-A1 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2006002088-A2 | AMINO-QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814372-B2 | Agonists of EPHA and their uses | EPHA2, EPHA7, EPHA1 | NPY1R 368/4885NPY5R 423/4885TP53 377/4885 |
| US-20090048265-A1 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE | ADRB1, ADRA2A, ADRA1A | NPY1R 2579/4885NPY5R 3209/4885TP53 133/4885 |
| US-20190002446-A1 | AGONISTS OF EPHA AND THEIR USES | EPHA2, EPHA7, EPHA1 | NPY1R 368/4885NPY5R 423/4885TP53 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.